The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting
Frontiers in Oncology · 03.12.2024 · 14
DOI: 10.3389/fonc.2024.1454844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 03.12.2024. Verfasst von Marcin Kubeczko und 8 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However, identifying prognostic biomarkers remains a challenge. Thus, we aimed to assess the prognostic value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) performed before CDK4/6 inhibitors initiation.
Methods
This single-center retrospective analysis comprised patients treated with CDK4/6 inhibitors in the second-line setting between 2018 and 2024, with FDG-PET-CT performed before CDK4/6 inhibitor initiation.
Results
The study included 39 patients with a median age of 63 years (IQR 50 -71). Among them, 12 had de novo metastatic disease (30.8%), and 13 had oligometastatic disease (33.3%). Treatment distribution was as follows: 15 patients received palbociclib (38%), 19 ribociclib (49%), and five abemaciclib (13%). Most patients received fulvestrant (31 patients, 79%), whereas eight patients (21%) were treated with letrozole. The median progression-free survival (PFS) in all studied patients was 25.8 months. Notably, baseline SUVmax (maximum standardized uptake value) showed statistically and clinically significant differences. Patients in the low SUVmax group had a median PFS of 30.7 months, compared to 13.0 months for those in the high SUVmax group (p = 0.038). The 2-year PFS was 76.2% [95% CI 51.8% - 89.4%] for the low SUVmax group, contrasting with 22.3% [95% CI 4.0% - 49.9%] for the high SUVmax group. High SUVmax, poor performance status, and de novo metastatic disease were independent prognostic factors for PFS.
Conclusions
FDG-PET-CT performed before cyclin-dependent kinase 4/6 inhibitor commencement is a valuable prognostic tool in hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. Patients with SUVmax less than 8.4 experienced extended progression-free survival compared to those with higher SUVmax.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
- Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
- Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
- Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Zitieren
APA
Kubeczko, M., Polakiewicz-Gilowska, A., D'Amico, A., Chrabański, O., Świderska, K., Chmielik, E., Blamek, S., Handkiewicz-Junak, D., & Jarząb, M. (2024). The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1454844
Vancouver
Kubeczko M, Polakiewicz-Gilowska A, D'Amico A, Chrabański O, Świderska K, Chmielik E, et al. The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1454844
BibTeX
@article{Kubeczko2024,
author = {Kubeczko, Marcin and Polakiewicz-Gilowska, Anna and D'Amico, Andrea and Chrabański, Olgierd and Świderska, Katarzyna and Chmielik, Ewa and Blamek, Sławomir and Handkiewicz-Junak, Daria and Jarząb, Michał},
title = {The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1454844}
}
EUVIMED